On September 10, 2015 NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, reported the commercial launch of the nCounter RNA:Protein PanCancer Immune Profiling Panel (Press release, NanoString Technologies, SEP 10, 2015, View Source [SID:1234507452]). The panel can be analyzed on the full line of nCounter Analysis Systems, including the new nCounter SPRINT Profiler, utilizing breakthrough technology, which simultaneously measures both RNA and Protein expression through multiplexed digital counting. Data generation from an early access program has demonstrated that the technology is robust, reproducible and sensitive, detecting both RNA and protein with as few as 150,000 cells in a single reaction.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Developing new cancer therapies and molecular diagnostics requires extracting all relevant biological information from clinical samples that are often too small to characterize using multiple different assays, such as small biopsies from recurrent tumors," said Martin McIntosh, Ph.D. of the Fred Hutchinson Cancer Research Center. "We now routinely quantify RNA and cell-surface protein abundance for these and other types of samples using the NanoString digital barcoding technology because we have found the information highly relevant, and even catalytic, in so many areas."
The RNA:Protein PanCancer Immune Profiling Panel from NanoString is the first example of an entirely new category of multiplexed digital assays, enabling the next generation of tumor profiling experiments. Most cancer biologists already perform RNA and protein expression analysis using separate methodologies when sufficient tumor sample is available. However, in many cases the analysis has been limited to RNA due to lack of sample. The RNA:Protein PanCancer Immune Profiling Panel offers a potential solution to this problem, by enabling simultaneous measurement of RNA and protein in small amounts of tumor sample—with 800 RNA and protein measurements in as few as 150,000 cells.
This initial immuno-oncology focused RNA:Protein Profiling Panel builds on the success of the company’s existing PanCancer Immune Profiling Panel for gene expression analysis. The new panel combines the measurement of 30 proteins with 770 RNA measurements to create a targeted immuno-oncology solution. The RNA measurements include genes indicated in the Hallmarks of Cancer, first described in seminal papers by Hanahan and Weinberg (Hanahan, D., and Weinberg, R.A. (2000). Cell 100, 57-70 and Hanahan, D., and Weinberg, R.A. (2011). Cell 144, 646-674), which identify immune cell types, cancer antigens, checkpoint blockades and key immune pathway genes for both innate adaptive and humoral immune responses. The protein measurements focus on cell surface and immune checkpoint targets indicated in the Cancer Immunity Cycle, first described by Chen and Mellman ( Chen DS, Mellman I. Immunity. 2013;39:1-10).
"NanoString is proud to be at the forefront of this new product category, providing our customers with the ability to measure gene and protein expression in a single experiment," said Joseph M. Beechem, Ph.D., Senior Vice President of Research & Development at NanoString Technologies. "We believe that our initial RNA:Protein Profiling Panel will become a powerful tool for immuno-oncology researchers, particularly those focused on drug development, where an understanding of protein interactions is critical."
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company’s nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in over 800 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company’s technology has also been applied to diagnostic use. The Prosigna Breast Cancer Prognostic Gene Signature Assay, together with the nCounter Dx Analysis System, is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer.
For more information, please visit www.nanostring.com.